Sofia Cristóvão-Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sofia Cristóvão-Ferreira has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Ana Maria Sebastião
Instituto de Farmacologia e Neurociências, Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
6 shared publications - Sandra Henriques Vaz
Instituto de Farmacologia e Neurociências, Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
5 shared publications - Joaquim Alexandre Ribeiro
Institute of Pharmacology and Neurosciences, Faculty of Medicine
4 shared publications - Emanuel Gouveia
Serviço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal
2 shared publications Ahmad Awada
Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Belgium
1 shared publicationAna M. Sebastião
University of Lisbon, Lisbon, Portugal
1 shared publication
Latest Publications
- Open Access
Enhanced expression of HLA-DR and CD69 on peripheral CD4 + T cells predicts better clinical outcomes in cutaneous melanoma
Background: Cutaneous melanoma (CM) is an aggressive skin cancer with rising incidence, representing a growing public health concern. Despite the remarkable success of immune-checkpoint inhibitors (ICIs) in the management of advanced disease, mortality remains high due to therapy resistance. Identifying reliable prognostic and predictive biomarkers is therefore essential to improve patient stratification, optimize treatment selection, and minimize unnecessary toxicity. Methods: We comprehensively profiled the circulating immune landscape of 54 treatment-naïve CM patients by integrating flow cytometry immunophenotyping with clinicopathological data, and performed tumor gene expression analysis in a subset of 26 patients. Results: Elevated HLA-DR and CD69 expression on circulating CD4 + T cells, together with reduced circulating CD8 + T cell frequency, emerged as candidate prognostic biomarkers associated with improved survival. Prognostic models combining these immune variables with clinical covariates accurately stratified patients by overall survival (89.5% sensitivity, 72.7% specificity; AUC = 0.872, p < 0.0001) and progression/recurrence risk (75% sensitivity and 71.4% specificity; AUC = 0.763, p = 0.001). In a subset of 43 patients subsequently treated with ICIs, elevated baseline HLA-DR and CD69 expression on circulating CD4 + T cells was also associated with therapeutic benefit. A predictive model integrating these markers with clinical covariates achieved good discriminatory performance (65.2% sensitivity, 88.9% specificity; AUC = 0.775, p = 0.0027). Tumor gene expression profiling supported the role of IFN-γ-related signatures, previously linked to ICI response, as complementary prognostic and predictive tools. Conclusion: These findings highlight systemic CD4 + T cell activation status as a promising, easily measurable biomarker in CM, laying the foundation for future strategies to refine patient stratification and guiding immunotherapy decisions.
Open AccessEnhanced expression of HLA-DR and CD69 on peripheral CD4 + T cells predicts better clinical outcomes in cutaneous melanoma
Background: Cutaneous melanoma (CM) is an aggressive skin cancer with rising incidence, representing a growing public health concern. Despite the remarkable success of immune-checkpoint inhibitors (ICIs) in the management of advanced disease, mortality remains high due to therapy resistance. Identifying reliable prognostic and predictive biomarkers is therefore essential to improve patient stratification, optimize treatment selection, and minimize unnecessary toxicity. Methods: We comprehensively profiled the circulating immune landscape of 54 treatment-naïve CM patients by integrating flow cytometry immunophenotyping with clinicopathological data, and performed tumor gene expression analysis in a subset of 26 patients. Results: Elevated HLA-DR and CD69 expression on circulating CD4 + T cells, together with reduced circulating CD8 + T cell frequency, emerged as candidate prognostic biomarkers associated with improved survival. Prognostic models combining these immune variables with clinical covariates accurately stratified patients by overall survival (89.5% sensitivity, 72.7% specificity; AUC = 0.872, p < 0.0001) and progression/recurrence risk (75% sensitivity and 71.4% specificity; AUC = 0.763, p = 0.001). In a subset of 43 patients subsequently treated with ICIs, elevated baseline HLA-DR and CD69 expression on circulating CD4 + T cells was also associated with therapeutic benefit. A predictive model integrating these markers with clinical covariates achieved good discriminatory performance (65.2% sensitivity, 88.9% specificity; AUC = 0.775, p = 0.0027). Tumor gene expression profiling supported the role of IFN-γ-related signatures, previously linked to ICI response, as complementary prognostic and predictive tools. Conclusion: These findings highlight systemic CD4 + T cell activation status as a promising, easily measurable biomarker in CM, laying the foundation for future strategies to refine patient stratification and guiding immunotherapy decisions.
- Open Access
- 6 February 2023
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 36 (7-8) , 487-495
Adjuvant Chemotherapy De-Escalation with Genomic Assay Protocol in Patients with Early Breast Cancer: A Single-Centre Prospective Cohort Study
Introduction: Genomic assays are useful tools for tailoring adjuvant treatment in early breast cancer. We aimed to analyse the role of an institutional protocol of a genomic assay for chemotherapy de-escalation.Methods: Prospective cohort study of all consecutive women diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative early breast cancer, tested with the 21-gene Recurrence Score (RS) assay from August 2015 to July 2018 at a Portuguese cancer centre. For being tested, patients should meet at least one of the pre-defined inclusion criteria: i) luminal A-like, pT2pN0; ii) luminal A-like, 1 – 3 positive nodes and comorbidities with higher risk of chemotherapy-induced toxicity; iii) pT1-2pN0, progesterone receptor ≤ 20% and/or Ki67 14% – 40%. Adjuvant treatment was de-escalated to isolated endocrine therapy if RS was less than 18. We measured the reduction in chemotherapy prescribing and its clinical impact, the RS association with pathologic features, and the protocol feasibility.Results: We tested 154 women with a median age of 61 years old (range: 25 – 79), 69% postmenopausal. Tumours were mainly pT1 (55%), pN0 (82%), invasive ductal (73%), G2 (86%), luminal B-like (69%) and stage IA (85%). We obtained a RS less than 18 in 60% of women, with an overall adjuvant chemotherapy reduction of 65%. Seven (95% confidence interval: 5 – 10) patients needed to be screened with the 21-gene RS assay to prevent one clinically relevant adverse event during the first six months of adjuvant treatment. Considering the currently used RS cut-off, only 9% of node-negative and 11% of node-positive patients had RS over 25. We found no relevant associations between RS and pathologic features. The protocol was feasible and did not compromise the adequate timing for adjuvant treatment.Conclusion: These criteria allowed the de-escalation of adjuvant systemic treatment in at least six out of ten women.
- 6 February 2023
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 36 (7-8) , 487-495
Open AccessAdjuvant Chemotherapy De-Escalation with Genomic Assay Protocol in Patients with Early Breast Cancer: A Single-Centre Prospective Cohort Study
Introduction: Genomic assays are useful tools for tailoring adjuvant treatment in early breast cancer. We aimed to analyse the role of an institutional protocol of a genomic assay for chemotherapy de-escalation.Methods: Prospective cohort study of all consecutive women diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative early breast cancer, tested with the 21-gene Recurrence Score (RS) assay from August 2015 to July 2018 at a Portuguese cancer centre. For being tested, patients should meet at least one of the pre-defined inclusion criteria: i) luminal A-like, pT2pN0; ii) luminal A-like, 1 – 3 positive nodes and comorbidities with higher risk of chemotherapy-induced toxicity; iii) pT1-2pN0, progesterone receptor ≤ 20% and/or Ki67 14% – 40%. Adjuvant treatment was de-escalated to isolated endocrine therapy if RS was less than 18. We measured the reduction in chemotherapy prescribing and its clinical impact, the RS association with pathologic features, and the protocol feasibility.Results: We tested 154 women with a median age of 61 years old (range: 25 – 79), 69% postmenopausal. Tumours were mainly pT1 (55%), pN0 (82%), invasive ductal (73%), G2 (86%), luminal B-like (69%) and stage IA (85%). We obtained a RS less than 18 in 60% of women, with an overall adjuvant chemotherapy reduction of 65%. Seven (95% confidence interval: 5 – 10) patients needed to be screened with the 21-gene RS assay to prevent one clinically relevant adverse event during the first six months of adjuvant treatment. Considering the currently used RS cut-off, only 9% of node-negative and 11% of node-positive patients had RS over 25. We found no relevant associations between RS and pathologic features. The protocol was feasible and did not compromise the adequate timing for adjuvant treatment.Conclusion: These criteria allowed the de-escalation of adjuvant systemic treatment in at least six out of ten women.
- Open Access
- 1 June 2021
- Published by Elsevier in The Breast
- Vol. 57, 86-94
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience
- 1 June 2021
- Published by Elsevier in The Breast
- Vol. 57, 86-94
Open AccessClinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience
- Open Access
- 1 May 2018
- Published by Elsevier in Cell Reports
- Vol. 23 (6) , 1678-1690
GAT-3 Dysfunction Generates Tonic Inhibition in External Globus Pallidus Neurons in Parkinsonian Rodents
- 1 May 2018
- Published by Elsevier in Cell Reports
- Vol. 23 (6) , 1678-1690
Open AccessGAT-3 Dysfunction Generates Tonic Inhibition in External Globus Pallidus Neurons in Parkinsonian Rodents
- Open Access
- 27 March 2017
- Published by SMC Media in European Journal of Case Reports in Internal Medicine
- Vol. 4 (2) , 000501
An Uncommon Cause of Diarrhoea and the Importance of an Internist Approach
An Uncommon Cause of Diarrhoea and the Importance of an Internist Approach
- 27 March 2017
- Published by SMC Media in European Journal of Case Reports in Internal Medicine
- Vol. 4 (2) , 000501
Open AccessAn Uncommon Cause of Diarrhoea and the Importance of an Internist Approach
An Uncommon Cause of Diarrhoea and the Importance of an Internist Approach
- 1 January 2017
- Published by Elsevier
- p. 45-76
Influence of Adenosine on Synaptic Excitability
- 10 May 2013
- Published by Springer Nature in Purinergic Signalling
- Vol. 9 (3) , 433-449
A1R–A2AR heteromers coupled to Gs and Gi/0 proteins modulate GABA transport into astrocytes
Astrocytes play a key role in modulating synaptic transmission by controlling extracellular gamma-aminobutyric acid (GABA) levels via GAT-1 and GAT-3 GABA transporters (GATs). Using primary cultures of rat astrocytes, we show here that a further level of regulation of GABA uptake occurs via modulation of the GATs by the adenosine A1 (A1R) and A2A (A2AR) receptors. This regulation occurs through A1R–A2AR heteromers that signal via two different G proteins, Gs and Gi/0, and either enhances (A2AR) or inhibits (A1R) GABA uptake. These results provide novel mechanistic insight into how GPCR heteromers signal. Furthermore, we uncover a previously unknown mechanism where adenosine, in a concentration-dependent manner, acts via a heterocomplex of adenosine receptors in astrocytes to significantly contribute to neurotransmission at the tripartite (neuron–glia–neuron) synapse.
- 10 May 2013
- Published by Springer Nature in Purinergic Signalling
- Vol. 9 (3) , 433-449
A1R–A2AR heteromers coupled to Gs and Gi/0 proteins modulate GABA transport into astrocytes
Astrocytes play a key role in modulating synaptic transmission by controlling extracellular gamma-aminobutyric acid (GABA) levels via GAT-1 and GAT-3 GABA transporters (GATs). Using primary cultures of rat astrocytes, we show here that a further level of regulation of GABA uptake occurs via modulation of the GATs by the adenosine A1 (A1R) and A2A (A2AR) receptors. This regulation occurs through A1R–A2AR heteromers that signal via two different G proteins, Gs and Gi/0, and either enhances (A2AR) or inhibits (A1R) GABA uptake. These results provide novel mechanistic insight into how GPCR heteromers signal. Furthermore, we uncover a previously unknown mechanism where adenosine, in a concentration-dependent manner, acts via a heterocomplex of adenosine receptors in astrocytes to significantly contribute to neurotransmission at the tripartite (neuron–glia–neuron) synapse.
- Open Access
- 1 November 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (47) , 40464-40476
Brain-derived Neurotrophic Factor (BDNF) Enhances GABA Transport by Modulating the Trafficking of GABA Transporter-1 (GAT-1) from the Plasma Membrane of Rat Cortical Astrocytes
- 1 November 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (47) , 40464-40476
Open AccessBrain-derived Neurotrophic Factor (BDNF) Enhances GABA Transport by Modulating the Trafficking of GABA Transporter-1 (GAT-1) from the Plasma Membrane of Rat Cortical Astrocytes